TORCH infections are a group of maternal infections that can cross from a pregnant person to their developing baby, sometimes causing serious birth defects, developmental delays, or pregnancy loss. The acronym stands for Toxoplasmosis, Other (historically syphilis, now expanded), Rubella, Cytomegalovirus (CMV), and Herpes simplex virus (HSV). Despite the tidy-sounding label, these infections differ wildly in how they spread, when they do the most damage, and what can be done about them. What they share is a dangerous ability to breach the placental barrier or infect the baby during delivery.
What the Acronym Covers and Why It Keeps Growing
The original TORCH panel grouped four pathogens that were recognized in the 1970s as common causes of congenital infection. The “O” in the middle was initially a catch-all for “Other,” primarily syphilis. Since then, researchers have argued repeatedly that the panel should expand. A review in the late 1980s called for adding agents beyond the original four, anticipating that the list would keep growing as diagnostic tools improved.1PubMed. Should we expand the TORCH complex? A description of clinical and diagnostic aspects of selected old and new agents That prediction proved accurate. Today, many clinicians fold in parvovirus B19, varicella-zoster, and Zika virus under the “O” umbrella, though the exact list varies by institution and region. The acronym is useful shorthand, but it can create the misleading impression that these are a single disease rather than very different infections with distinct biology.
How the Placenta Normally Keeps Pathogens Out
The human placenta is not just a passive membrane. It actively restricts microbial access to the developing fetus through layers of specialized cells and immune molecules.2PubMed Central. Microbial Vertical Transmission during Human Pregnancy One line of defense involves interferon signaling triggered by short stretches of repetitive DNA embedded in the placental genome. These DNA elements produce molecules that mimic viral RNA, which tricks the placenta’s immune sensors into maintaining a constant low-level antiviral state, even when no infection is present.3Cell Host & Microbe. SINE RNA of the imprinted miRNA clusters mediates constitutive type III interferon expression and antiviral protection in hemochorial placentas TORCH pathogens are dangerous precisely because they have evolved ways to slip past or overwhelm these defenses, each by a different route. Toxoplasma gondii, for instance, can actively invade placental cells, while CMV hijacks immune cells that travel across the placental boundary.
Toxoplasmosis and the Timing Paradox
Toxoplasma gondii is a parasite most people associate with cat litter, though undercooked meat and contaminated water are equally common routes of exposure. When a person is infected for the first time during pregnancy, the parasite can cross the placenta. The chance of this happening increases sharply as pregnancy advances, from roughly 6% at 13 weeks of gestation to about 72% at 36 weeks.4The Lancet. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis But here is the paradox: infections that cross early tend to cause far more severe damage. The timing of primary maternal infection is critically linked to how the baby is affected.5PubMed. Congenital toxoplasmosis–prenatal aspects of Toxoplasma gondii infection
When transmission happens early, the consequences can include intracranial calcifications, hydrocephalus, and a characteristic eye infection called retinochoroiditis.6PubMed. Congenital toxoplasmosis: An overview of the neurological and ocular manifestations The eye damage deserves particular attention because it can appear or worsen years after birth. In one long-term study, chorioretinal scars were the most common eye finding, and macular scars were present in over half of treated patients, with visual acuity in affected eyes ranging from normal to severely impaired.7PubMed. Eye manifestations of congenital toxoplasmosis Babies infected later in pregnancy are more likely to be born without obvious symptoms but can still develop problems down the line, making follow-up essential.
Congenital Syphilis Is Making a Comeback
Syphilis, caused by the bacterium Treponema pallidum, is one of the oldest recognized congenital infections. It is also, in theory, one of the most preventable: a simple blood test during pregnancy followed by penicillin treatment can stop transmission almost entirely. Yet case rates have been climbing. The global rate of congenital syphilis reached 425 cases per 100,000 live births in 2020, far above the World Health Organization’s elimination target of 50 per 100,000.8PubMed. Resurgence of congenital syphilis: new strategies against an old foe The trend has continued upward, with prevalence rising from 203 per 100,000 in 2015 to 295 per 100,000 in 2021 by another estimate.9PubMed. Congenital syphilis: adverse pregnancy outcomes and neonatal disorders
The resurgence is tied to rising rates of syphilis among women of reproductive age, gaps in prenatal care access, missed or late screening, and cases where diagnosis is made but treatment is not completed in time.10PubMed Central. The Reemergence of Congenital Syphilis-Maternal and Fetal Risks and Consequences Untreated syphilis during pregnancy can cause stillbirth, preterm delivery, and a wide range of problems in surviving infants, from skin rashes and bone abnormalities to organ damage. The frustrating reality is that penicillin remains cheap and effective, which makes every case of congenital syphilis, in a meaningful sense, a failure of the healthcare system rather than a failure of medicine.
Cytomegalovirus, the Most Common and Least Known
CMV is the most frequent congenital infection in high-income countries, yet most people have never heard of it. It belongs to the herpesvirus family and spreads through saliva, urine, and other body fluids. Unlike toxoplasmosis or syphilis, CMV can be transmitted to the fetus even when the mother has been previously infected and carries existing antibodies. While the most severe cases tend to follow a first-time infection during pregnancy, growing evidence shows that secondary maternal infections (reactivation of an old infection, or infection with a new strain) contribute to a larger proportion of symptomatic congenital CMV than researchers previously assumed.11PubMed Central. Secondary cytomegalovirus infections: How much do we still not know? One study found that over 60% of babies infected with CMV in utero were born to mothers who already had immunity before pregnancy.12PubMed. Fetal effects of primary and secondary cytomegalovirus infection in pregnancy
That said, the transmission rates differ substantially. Another study found a 0% fetal transmission rate among women with non-primary infections, though the confidence interval was wide enough (0–3.5%) that rare transmission cannot be ruled out.13PubMed. Human cytomegalovirus non-primary infection during pregnancy: antibody response, risk factors and newborn outcome The discrepancy between studies reflects how difficult it is to classify maternal CMV status accurately, especially when reinfection with a different viral strain can look a lot like reactivation of an old one.
Most babies born with congenital CMV appear healthy at birth, which is part of the problem. Among those classified as asymptomatic, the cumulative rate of sensorineural hearing loss over the first five or more years of life runs between 7% and 11%, much higher than in uninfected children.14PubMed. Hearing and neurodevelopmental outcomes for children with asymptomatic congenital cytomegalovirus infection: A systematic review For babies with obvious symptoms at birth, the hearing loss rate is far higher, in the range of 34–41%. Because hearing loss from CMV can be delayed in onset and progressive, children infected at birth need monitoring well beyond infancy.
Rubella and the Power of Vaccination
Rubella, once called German measles, offers the clearest success story in the TORCH group. Congenital rubella syndrome (CRS) can cause a devastating triad of heart defects, cataracts, and hearing loss when infection occurs during the first trimester. The virus targets developing cardiac tissue and the lens of the eye with particular ferocity.15PubMed Central. Clinically Confirmed Congenital Rubella Syndrome: The Role of Echocardiography In countries with high MMR vaccination coverage, CRS has become exceedingly rare. But in regions with lower vaccination rates, rubella outbreaks still occur, and CRS remains a real threat. Because rubella vaccination cannot be given during pregnancy (it is a live vaccine), immunity needs to be established before conception.
Herpes Simplex and the Delivery Window
Unlike most other TORCH pathogens, herpes simplex virus (HSV) rarely causes damage during pregnancy itself. The overwhelming majority of neonatal herpes infections, roughly 85%, are acquired during delivery as the baby passes through the birth canal. Another 10% result from postnatal contact, and only about 5% are true intrauterine infections.16PubMed. Neonatal herpes simplex virus infection: From the maternal infection to the child outcome The risk is highest when a mother acquires a new genital herpes infection near the time of delivery, because her body has not yet produced antibodies that could offer the baby some protection. Recurrent outbreaks carry a much lower transmission risk, though they are not zero risk.17JAMA. Effect of Serologic Status and Cesarean Delivery on Transmission Rates of Herpes Simplex Virus From Mother to Infant Cesarean delivery when active lesions are present is one of the most effective interventions.
Parvovirus B19 and Zika as Newer Additions
Parvovirus B19, the virus behind “fifth disease” (the mild childhood illness with a slapped-cheek rash), has a specific appetite for red blood cell precursors. When a non-immune pregnant person is infected, the virus can cross the placenta and attack the fetal blood supply. In most cases, the fetus is not harmed. But in severe instances, particularly when infection occurs in the first or second trimester, the baby can develop profound anemia, a dangerous fluid buildup called hydrops, or pregnancy loss.18PubMed Central. Parvovirus B19 Infection and Pregnancy: Review of the Current Knowledge There is no vaccine and no antiviral for parvovirus B19, so management relies on monitoring and, in severe cases, intrauterine blood transfusion.
Zika virus earned global attention after the 2015–2016 epidemic in the Americas revealed its devastating effects on fetal brain development. The virus targets neural progenitor cells, the precursor cells that build the brain’s outer layers.19Cell Stem Cell. Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice By killing or stunting these cells, Zika can cause microcephaly (an abnormally small head), cortical thinning, and malformation of brain structures.20PubMed. Neuroteratogenic mechanisms of Zika virus (ZIKV) infection: Insights into fetal brain development disruption and congenital Zika syndrome Researchers believe the virus spreads through the embryonic brain primarily by traveling along neurons, which explains why damage often concentrates in particular brain regions rather than spreading uniformly.21PubMed Central. Zika virus infection histories in brain development Though Zika transmission has decreased markedly since the epidemic peak, the virus remains endemic in tropical regions.
Why Diagnosis Is Trickier Than a Simple Blood Test
Standard prenatal screening for TORCH infections relies on measuring antibodies in the mother’s blood, specifically IgM (which tends to rise during acute infection) and IgG (which indicates past exposure and immunity). The trouble is that IgM can persist for months after an infection, making it hard to distinguish a new infection from an old one using antibodies alone.22KESANS : International Journal of Health and Science. Innovative Diagnostic Approaches for TORCH Infections in Pregnancy: The Role of IgG Avidity and Affinity-Switchable Lateral Flow Assays IgG avidity testing, which measures how tightly antibodies bind to their target, can help: low-avidity IgG suggests a recent infection, while high avidity points to an older one. This is especially useful for CMV and toxoplasmosis. But avidity assays require specialized laboratory equipment and are unavailable in many settings, particularly in lower-income regions where TORCH infections are most common.
For the baby, direct detection of the pathogen can be more informative than maternal antibodies. PCR testing of amniotic fluid can identify toxoplasmosis or CMV DNA in utero. After birth, testing the baby’s saliva or urine for CMV within the first two to three weeks of life is considered the gold standard for confirming congenital CMV. Dried blood spots collected at birth can also be tested using PCR, but the sensitivity is limited. In one large screening study, a single-primer PCR assay on dried blood spots detected congenital CMV with a sensitivity of only about 28%, meaning it missed the majority of infected babies.23PubMed Central. Dried Blood Spot Real-Time Polymerase Chain Reaction Assays to Screen Newborns for Congenital Cytomegalovirus Infection This is why newborn hearing screening, rather than blood testing, has been the more common pathway to identifying babies who need further evaluation for CMV.
Long-Term Neurodevelopmental Effects
The consequences of congenital TORCH infections do not end at birth. A large Swedish study tracking over 3.6 million individuals found that those born with a TORCH infection faced substantially elevated risks of intellectual disability and autism compared to uninfected peers. The risk increase was roughly sevenfold for intellectual disability and threefold for autism, and these associations held up even in sibling comparisons, which helps account for shared family genetics and environment.24JAMA Pediatrics. Congenital TORCH Infections and Neurodevelopmental Outcomes Risks were highest for more severe forms of intellectual disability. Exposed children also scored lower on school assessments in adolescence.
Even babies who appear healthy at birth are not necessarily in the clear. In a cohort study following infected children over their first two years, about a quarter of those classified as asymptomatic at birth had developed problems by 24 months, compared to roughly 69% of those who had symptoms from the start.25PubMed Central. Maternal–Fetal Infections (Cytomegalovirus, Toxoplasma, Syphilis): Short-Term and Long-Term Neurodevelopmental Outcomes in Children Infected and Uninfected at Birth The practical lesson: “asymptomatic at birth” should not be confused with “unaffected.” Extended follow-up, including hearing tests, vision checks, and developmental monitoring, matters for any child known to be congenitally infected.
Treatments and Vaccines on the Horizon
Treatment options for TORCH infections are a patchwork. Syphilis is treated with penicillin, and when given early enough in pregnancy, the results are excellent. Toxoplasmosis is treated with a combination of pyrimethamine and sulfadiazine along with folinic acid supplementation. For congenital CMV, antiviral medications like ganciclovir and its oral form valganciclovir can reduce hearing loss progression in symptomatic babies, though they carry significant side effects including bone marrow suppression.26University of Thi-Qar Journal of Science. TORCH Infection during Pregnancy: A Comprehensive Review from Diagnosis to Treatment For rubella, the answer is prevention through vaccination before pregnancy.
The biggest unmet need is a CMV vaccine. Because CMV is the most common congenital infection and has no approved vaccine, significant resources are being directed at development. An mRNA-based CMV vaccine candidate, mRNA-1647, showed an acceptable safety profile and triggered both antibody and cellular immune responses in a first-in-human phase 1 trial involving both CMV-positive and CMV-negative adults.27PubMed Central. Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1 Randomized Clinical Trial Larger efficacy trials are underway. If a CMV vaccine proves effective and is widely adopted, it could prevent more congenital infections than any other single intervention in this space.
Who Gets Tested and Who Gets Missed
Access to TORCH screening is not evenly distributed. A large analysis of women of childbearing age across different provinces in China found that the proportion of women identified as at-risk for TORCH infections varied significantly by region, ethnicity, education level, and age. Higher education was consistently associated with lower risk, a pattern likely reflecting both awareness of preventive measures and better access to healthcare.28PubMed Central. Analysis of TORCH screening and prenatal risk assessment for childbearing-age women in different regions of China These disparities are not unique to any one country. In the United States, the recent surge in congenital syphilis has disproportionately affected communities with limited prenatal care, particularly in rural areas and among populations facing economic barriers to healthcare.
Universal screening policies also differ by infection. Most countries screen pregnant women for syphilis and rubella immunity. Routine screening for toxoplasmosis is standard in France but uncommon in the United States or United Kingdom. Universal CMV screening remains controversial: because the virus is so common and most congenital infections are asymptomatic at birth, many experts worry that screening would cause more anxiety than benefit without clear management pathways. The counterargument is that identifying infected newborns early enables hearing monitoring and, when needed, antiviral treatment during the critical window when it can make the most difference.
The Emotional Weight of a Positive Result
A diagnosis of TORCH infection during pregnancy or in a newborn is not just a medical event. Parents face agonizing uncertainty, especially when ultrasound shows brain abnormalities whose long-term significance is unclear. In cases where severe fetal anomalies are detected, families may be confronted with decisions about continuing or terminating the pregnancy, a choice that carries profound emotional and often moral weight regardless of which path is taken. Studies of parents in these situations consistently find high rates of distress and post-traumatic stress reactions.29Nigerian Journal of Clinical Practice. Ethical and legal dilemmas around termination of pregnancy for severe fetal anomalies Support from genetic counselors and mental health professionals is a critical but frequently underresourced part of managing these infections, and families benefit from knowing that emotional fallout is normal and expected rather than a sign of weakness.